Loading
NASDAQHealthcareBiotechnology
Latest quote
$8.88
+$0.12 · +1.37%
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Previous close
$8.88
+$0.12 · +1.37%
Pre-market
$8.61
−$0.27 · -3.04%
Oct 8, 4:13 AM ET
Regular session · ET · Market data may be delayed.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Day range
Current $8.88
52-week range
Current $8.88
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
37
Expensive
Sentiment
44
Mixed
Risk
76
High Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Day range
Current $8.88
52-week range
Current $8.88
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 2M USD | — | — |
| Gross profit | — | — | 2M USD | — | — |
| Research and development | 39.05M USD | 38.44M USD | 19.78M USD | 24.92M USD | 19.34M USD |
| Selling, general, and administrative | 17.84M USD | 16.01M USD | 12.96M USD | 6.14M USD | 4.38M USD |
| Operating expenses | 56.89M USD | 54.45M USD | 32.74M USD | 31.06M USD | 23.72M USD |
| Interest income | 5.85M USD | 8.89M USD | 2.86M USD | 553K USD | 26K USD |
| Depreciation and amortization | — | — | — | 130K USD | — |
| Operating income | −56.89M USD | −54.45M USD | −30.74M USD | −31.06M USD | −23.72M USD |
| Net income | −51.04M USD | −45.57M USD | −27.88M USD | −30.5M USD | −24.44M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.00
125.23% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI19.1M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM13.5M0.02%78.56B USD0.19%$277.7-1.29%
State Street SPDR S&P Biotech ETFXBI11.59M0.11%10.08B USD0.35%$150.23-0.44%
Vanguard Extended Market ETFVXF6.85M0.01%95.4B USD0.05%$233.49-1.56%
iShares Biotechnology ETFIBB3.81M0.04%10.4B USD0.44%$203.34+0.12%
iShares Russell 2000 Growth ETFIWO3.7M0.03%14.25B USD0.24%$355.37-1.43%
Vanguard Russell 2000 ETFVTWO3.46M0.02%18B USD0.06%$112.21-1.26%
Dimensional - US Small Cap ETFDFAS2.33M0.01%33.66B USD0.31%$77.92-1.38%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
